Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study

References

• Akash MSH, Rehman K, Liaqat A, Numan M, Mahmood Q, Kamal S. Biochemical investigation of gender-specific association between insulin resistance and inflammatory biomarkers in types 2 diabetic patients. Biomed Pharmacother. 2018;106:285–291. doi:10.1016/j.biopha.2018.06.04429966972
   PubMed Web of Science ®Google Scholar
• Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100–109. doi:10.1016/j.cyto.2016.06.02827498215
   PubMed Web of Science ®Google Scholar
• Kanwal R, Akash MSH. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? Biomed Sci. 2016;23:87. doi:10.1186/s12929-016-0303-y
   Google Scholar
• Wegner M, Araszkiewicz A, Piorunska-Stolzmann M, Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D. Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation. 2013;36:723–728. doi:10.1007/s10753-013-9598-y23371411
   PubMed Web of Science ®Google Scholar
• D’Amico AG, Maugeri G, Rasà DM, et al. Modulation of IL-1β and VEGF expression in rat diabetic retinopathy after PACAP administration. Peptides. 2017;97:64–69. doi:10.1016/j.peptides.2017.09.01428964802
   PubMed Web of Science ®Google Scholar
• Capitão M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J Cell Biochem. 2016;117:2443–2453. doi:10.1002/jcb.2557527128219
   PubMed Web of Science ®Google Scholar
• Sheikh V, Zamani A, Mahabadi-Ashtiyani E, Tarokhian H, Borzouei S, Alahgholi-Hajibehzad M. Decreased regulatory function of CD4CD25CD45RA T cells and impaired IL-2 signalling pathway in patients with T2DM. Scand J Immunol. 2018;88(4):e12711. doi:10.1111/sji.2018.88.issue-430270447
   PubMed Web of Science ®Google Scholar
• Domingueti CP, Dusse LMS, das Graças Carvalho M, et al. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. Diabetes Complicat. 2016;30:738–745. doi:10.1016/j.jdiacomp.2015.12.018
   PubMed Web of Science ®Google Scholar
• Mascitelli L, Goldstein MR, Zacharski LR, et al. Association of multiple biomarkers of iron metabolism and type 2 diabetes: the EPIC-interact study. Diabetes Care. 2016;39:572–581. doi:10.2337/dc15-025726861925
   PubMed Web of Science ®Google Scholar
• Andrews M, Soto N, Arredondo M, et al. Effect of metformin on the expression of tumor necrosis factor-α, toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients. Rev Med Chil. 2012;140(11):1377–1382. doi:10.4067/S0034-9887201200110000123677182
   PubMed Web of Science ®Google Scholar
• Jager J, Kooy A, Schalkwijk C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014;275(1):59–70. doi:10.1111/joim.1212823981104
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.9742977
   PubMed Web of Science ®Google Scholar
• Griffin Simon J, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620–1629. doi:10.1007/s00125-017-4337-928770324
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, D’Angelo A, et al. Acarbose on insulin resistance after an oral fat load: a double-blind, placebo-controlled study. J Diabetes Complications. 2011;25:258–266. doi:10.1016/j.jdiacomp.2011.01.00321367625
   PubMed Web of Science ®Google Scholar
• Giuseppe D, Pamela M, Ilaria F, et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol. 2011;651(1–3):240–250. doi:10.1016/j.ejphar.2010.11.01521118681
   PubMed Web of Science ®Google Scholar
• Chiasson J-L. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial. Endocr Pract. 2006;12(Supplement 1):25–30. doi:10.4158/EP.12.S1.2516627376
   PubMedGoogle Scholar
• Markolf H. Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus). Endocr Pract. 2006;12(Supplement 1):56–59. doi:10.4158/EP.12.S1.56
   Google Scholar
• Phosat C, Panprathip P, Chumpathat N, et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural thais: a cross-sectional study. BMC Endocr Disord. 2017;17(1):44. doi:10.1186/s12902-017-0189-z28716139
   PubMed Web of Science ®Google Scholar
• Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63(3):1115–1123. doi:10.2337/db12-162524222348
   PubMed Web of Science ®Google Scholar
• Hsieh MC, Tien KJ, Chang SJ, et al. High sensitivity C-reactive protein and silent myocardial ischemia in Chinese with type 2 diabetes mellitus. Metabolism. 2008;57(11):1533–1538. doi:10.1016/j.metabol.2008.06.00718940390
   PubMed Web of Science ®Google Scholar
• Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6, expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745–E751. doi:10.1152/ajpendo.2001.280.5.E74511287357
   PubMed Web of Science ®Google Scholar
• Kothari V, Galdo JA, Mathews ST. Hypoglycemic agents and potential anti-inflammatory activity. J Inflamm Res. 2016;9:27–38.27114714
   PubMed Web of Science ®Google Scholar
• Saisho Y. Metformin and inflammation: its potential beyond glucose lowering effect. Endocr Metab Immune Disord Drug Targets. 2015;15:196–205. doi:10.2174/187153031566615031612401925772174
   PubMed Web of Science ®Google Scholar
• Zheng Z, Chen H, Li J, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 2012;61:217–228. doi:10.2337/db11-129622124463
   PubMed Web of Science ®Google Scholar
• Han X 1, Wang B 1, Sun Y 1, et al. Metformin modulates high glucose-incubated human umbilical vein endothelial cells proliferation and apoptosis through AMPK/CREB/BDNF pathway. Front Pharmacol. 2018;9:1266. doi:10.3389/fphar.2018.0126630459620
   PubMed Web of Science ®Google Scholar
• Chen P-H, Tsai Y-T, Wang J-S, et al. Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose. Diabetol Metab Syndr. 2014;6:68.24932223
   PubMed Web of Science ®Google Scholar
• Fukaya N, Mochizuki K, Shimada M, et al. The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. Nutrition. 2009;25:657–667. doi:10.1016/j.nut.2008.11.01519216056
   PubMed Web of Science ®Google Scholar
• Khajehdehi P, Roozbeh J, Mostafavi H, et al. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type 2 diabetic nephropathy. Scand J Urol Nephrol. 2002;36(2):145–148. doi:10.1080/00365590275367945412028688
   PubMed Web of Science ®Google Scholar
• Sun X, Han F, Yi J, Han L, Wang B. Effect of aspirin on the expression of hepatocyte NF-kappa B and serum TNF-alpha in streptozotocin-induced type 2 diabetic rats. J Korean Med Sci. 2011;26:765–770. doi:10.3346/jkms.2011.26.6.76521655062
   PubMed Web of Science ®Google Scholar
• Jiang XZ, Zhe G, Bin Z, et al. Effects of aspirin on inflammatory factors of type 2 diabetes mellitus patients. Chin J New Drugs and Clin Remedies. 2009;28(4):297–300.
   Google Scholar
• Shu Z, Jinshan W, Qing Z, et al. Effect of atorvastatin and rosiglitazone on inflammatory factors in patients with type 2 diabetes mellitus association with unstable angina. J Qingdao Univ. 2009;45(3):274–276.
   Google Scholar
• Ukinc K, Ersoz HO, Erem C, Hacihasanoglu AB, Karti SS. Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine. 2009;35:380–388. doi:10.1007/s12020-009-9157-319259830
   PubMed Web of Science ®Google Scholar
• Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species(ROS)generation in leucocytes, nuclear factor-KB (NF-KB), and activator protein-l (AP-1) in mononuclear cells (MNC) of normal subjects: evidence of an anti-inflammation action. J Clin Endocrinol Metab. 2003;88(9):496–4501.
   Web of Science ®Google Scholar
• Pavlatou MG, Mastorakos G, Margeli A, et al. Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation. Eur J Clin Invest. 2011;41:652–658. doi:10.1111/j.1365-2362.2010.02453.x21175613
   PubMed Web of Science ®Google Scholar
• DREAM on Investigators, Gerstein HC, Mohan V, et al. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 2011;54(3):487–495. doi:10.1007/s00125-010-1985-421116607
   PubMed Web of Science ®Google Scholar
• Shahinfar S, Lyle PA, Zhang Z, Keane WF, Brenner BM. Losartan: lessons learned from the RENAAL study. Expert Opin Pharmaco Ther. 2006;7(5):623–630. doi:10.1517/14656566.7.5.623
   PubMed Web of Science ®Google Scholar
• Araujo EP, De Souza CT, Ueno M, et al. Infliximab restores glucose homeostasis in an animal model of diet‐induced obesity and diabetes. Endocrinology. 2007;148:5991–5997. doi:10.1210/en.2007-013217761768
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K, Sun H, Chen S. Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic goto-kakizaki-rats. Eur J Pharmacol. 2013;701:87–95. doi:10.1016/j.ejphar.2013.01.00823348707
   PubMed Web of Science ®Google Scholar